Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 2012

View Archived Issues

Tenascin-C evaluated as a marker of isolated noncompaction cardiomyopathy

DNA decoy to prevent postsurgical pain shows promising preclinical toxicity profile

Preclinical data support clinical testing of new antiarrhythmic drug

Theravance product shows strong antinociceptive activity across a range of pain models

Jakavi approved in Europe

European Commission approves Zinforo

Novel agent is active against West Nile virus and other flaviviruses / News in Context

Bristol-Myers Squibb presents in vivo results on new Trk inhibitors

New potential cancer therapies developed at U.S. university

Genmab designs novel CD74-directed immunotherapies

Novel candidate HIV medicines presented by Bristol-Myers Squibb

Scientists in U.S. disclose novel HDAC inhibitors

Boehringer Ingelheim Pharma patents new PI3K-alpha inhibitors

New MDR efflux pump inhibitors synthesized in France

Esperance advances phase II trial in ovarian cancer

New assay to measure testosterone obtains CE mark

FDA committee to discuss Heplisav BLA

Biomarker has prognostic value in patients with diabetes and coronary artery disease

Cangene strengthens biodefense work

Resverlogix reports topline results from SUSTAIN study

Health Canada approves Treanda

Altheus Therapeutics kicks off phase II trial in ulcerative colitis

Novelos Therapeutics developing optical imaging agent for use in cancer

First patient enrolled in phase IIa AEZS-130 study

CE Mark approval for Elixir Medical stent

Pristine Solutions completes acquisition

Promising phase IIa data reported on Archexin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...